The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.
about
Concise Review: CXCR4/CXCL12 Signaling in Immature Hematopoiesis--Lessons From Pharmacological and Genetic ModelsContinuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cellsNovel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs)Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALLCXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathwayEffectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice.Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.In vitro-engineered non-antibody protein therapeutics.Functional consequences of perturbed CXCL12 signal processing: analyses of immature hematopoiesis in GRK6-deficient mice.Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.CXCR4-directed theranostics in oncology and inflammation
P2860
Q28080830-D477EF5B-E33C-4B21-9B72-03E54FDDA918Q33731221-0C462C60-6BC2-4DA2-AC58-030C118B956EQ34253089-DA9A9C49-2BC2-4A98-A944-882C05EA2885Q34654670-294786DA-59CE-4884-8B64-B12EA35CD3D6Q36544455-F74A26C7-9666-4AFA-96E8-9C5B78671AA7Q36668951-71032472-3F00-461A-913F-B9267C394157Q36771955-4A5CAD15-328E-4F0A-B663-CCD69C8D5E33Q37099769-BCA22A4D-DF0C-406B-827B-15AFAA46C9EDQ37554951-7D49DA72-15FA-4CF6-9EEF-652EB1495D1EQ38199707-4EEE4745-D2C7-4B6E-ABC6-7A56FCA3DF8EQ38223391-F082C8D5-D22B-4A74-B6ED-0F52A9F09FF4Q38880504-394AEB1D-ACB1-460D-AA87-780437E448B9Q38947056-5B071857-1DB3-4A31-9859-F3C2F0575726Q39167522-897D8CD9-E1C8-40A8-8DA8-90CFAC2E4817Q42117966-BFB323E4-DC54-472D-A4A6-4A3378C96CBCQ48184079-639E1A39-BA3D-4927-8CC0-D8D71AA064B0Q58783862-E4C25FB2-10D6-403F-A958-36CEF89FF8BE
P2860
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The novel CXCR4 antagonist POL ...... er efficiency than Plerixafor.
@en
The novel CXCR4 antagonist POL ...... er efficiency than Plerixafor.
@nl
type
label
The novel CXCR4 antagonist POL ...... er efficiency than Plerixafor.
@en
The novel CXCR4 antagonist POL ...... er efficiency than Plerixafor.
@nl
prefLabel
The novel CXCR4 antagonist POL ...... er efficiency than Plerixafor.
@en
The novel CXCR4 antagonist POL ...... er efficiency than Plerixafor.
@nl
P2093
P2860
P50
P356
P1433
P1476
The novel CXCR4 antagonist POL ...... ter efficiency than Plerixafor
@en
P2093
B Romagnoli
D Chudziak
E Chevalier
E Wiercinska
K Dembowsky
P2860
P2888
P304
P356
10.1038/LEU.2013.266
P577
2013-09-12T00:00:00Z